Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Shinichi Yaguchi"'
Autor:
Naomi Tamaki, Kanami Yamazaki, Yumiko Nishimura, Yuya Yoshizawa, Shingo Dan, Shinichi Yaguchi, Nachi Namatame, Mutsumi Okamura
Publikováno v:
Cancer Research. 79:3909-3909
Phosphatidylinositol-3 kinase (PI3K) is a key signaling molecule for tumor growth and survival, thus the PI3K pathway has been thought to be a promising target for cancer therapy. We previously identified a novel phosphatidylinositol-3 kinase (PI3K)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64b963ee26f9cc6d64f285923980bcfa
https://doi.org/10.1158/1538-7445.am2019-3909
https://doi.org/10.1158/1538-7445.am2019-3909
Autor:
Naoto Tamura, Shinichi Yaguchi, Asako Sasaki, Fumitaka Kamachi, Jumpei Enami, Kazuhiko Haruta, Shigeyuki Mori, Masakazu Nagamine, Shigeto Kobayashi, Takao Yamori, Yoshinari Takasaki
Publikováno v:
Inflammation Research. 61:551-562
We examined the effects of ZSTK474, a phosphatidylinositol 3-kinase (PI3K) inhibitor, on adjuvant-induced arthritis (AIA).AIA was induced in Lewis rats by subcutaneous administration of Freund's complete adjuvant at the base of the tail on day 0. ZST
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c6c02782e486b3c2b31d84e2620318
https://doi.org/10.1007/s00011-012-0444-8
https://doi.org/10.1007/s00011-012-0444-8
Publikováno v:
Biological and Pharmaceutical Bulletin. 32:297-300
Phosphatidylinositol 3-kinase (PI3K) has been implicated in a variety of diseases including cancer. A number of PI3K inhibitors have recently been developed for use in cancer therapy. ZSTK474 is a highly promising antitumor agent targeting PI3K. We p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9580b230f4b1c55031acf22bbf6d131b
https://doi.org/10.1248/bpb.32.297
https://doi.org/10.1248/bpb.32.297
Autor:
Yasuhisa Fukui, Shinichi Yaguchi, Takao Yamori, Hisashi Yoshimi, Toshiyuki Matsuno, Kanami Yamazaki, Shuichi Hirono, Ichiro Koshimizu, Hiroaki Gouda
Publikováno v:
JNCI: Journal of the National Cancer Institute. 98:545-556
Background We previously synthesized a novel s-triazine derivative, ZSTK474 [2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine], that strongly inhibited the growth of tumor cells. We identified its molecular target, investigated i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::060b250123b5484410ba19899d0c010b
https://doi.org/10.1093/jnci/djj133
https://doi.org/10.1093/jnci/djj133
Autor:
Shingo Dan, Emiko Sekine-Suzuki, Takao Yamori, Shinichi Yaguchi, Kazunori Anzai, Mutsumi Okamura, Ryuichi Okayasu, Hisashi Yoshimi, Jumpei Enami, Megumi Ueno
Publikováno v:
Cancer science. 102(6)
ZSTK474 is a novel orally applicable PI3K-specific inhibitor and strongly inhibits cancer cell proliferation. To explore further the antitumor effect of ZSTK474 for future clinical usage, combined effects with radiation were studied. The proliferatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c56d161120c171da1944ff0047ecab
https://pubmed.ncbi.nlm.nih.gov/21352422
https://pubmed.ncbi.nlm.nih.gov/21352422
Autor:
Sumio Terada, Shinichi Yaguchi, Toshiyuki Matsuno, Masayuki Takahashi, Masanobu Kato, Yoshio Tsuchida
Publikováno v:
ChemInform. 28
Triamino-substituted 1, 3, 5-triazine derivatives were synthesized and tested for inhibitory activities against the aromatase of human lacental microsomes and the cytochrome P450 side chain cleavage of cholesterol (P450SCC) of pig adrenal mitochondri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::369b776de8af6bef9558635fc6182a1c
https://doi.org/10.1002/chin.199735187
https://doi.org/10.1002/chin.199735187
Autor:
Shinichi Yaguchi, Katsuyasu Sakita, Yasuhiro Izumisawa, Masanobu Kato, Ichiro Koshimizu, Kimitomo Yoshioka, Tsutomu Nakagane, Seiichiro Kawashima, Makoto Sato, Mitsuo Sakato
Publikováno v:
Biological and Pharmaceutical Bulletin. 20:698-700
We examined in vitro cytotoxic activity of imidazolyl-1, 3, 5-triazine derivatives using human breast cancer cell lines (MCF-7, R-27, T-47D and ZR-75-1) and murine leukemia cell line (P388). The percentage of viable cells was determined by the 3-(4,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9e3a958f49e0c6babcfaff4c15d5375
https://doi.org/10.1248/bpb.20.698
https://doi.org/10.1248/bpb.20.698
Autor:
Masanobu Kato, Tetsuo Watanabe, Hiroya Sasahara, Seiichiro Kawashima, Masahiro Inaba, Shinichi Yaguchi, Toshiyuki Matsuno, Mitsuo Sakato, Kimitomo Yoshioka, Masayuki Takahashi
Publikováno v:
ChemInform. 32
Triamino-substituted 1,3,5-triazine and pyrimidine derivatives were synthesized and tested for antitumor activities using some human cancer cell lines and murine leukemia cell lines. All the compounds having benzimidazolyl and morpholino groups as su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8feb840ce8db91211597f953b2917b3b
https://doi.org/10.1002/chin.200113155
https://doi.org/10.1002/chin.200113155
Autor:
Sumio Terada, Yoshio Tsuchida, Toshiyuki Matsuno, Masayuki Takahashi, Masanobu Kato, Shinichi Yaguchi
Publikováno v:
Chemicalpharmaceutical bulletin. 45(2)
Triamino-substituted 1, 3, 5-triazine derivatives were synthesized and tested for inhibitory activities against the aromatase of human lacental microsomes and the cytochrome P450 side chain cleavage of cholesterol (P450SCC) of pig adrenal mitochondri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b59d464bf97ea8037e9c013929cd05
https://pubmed.ncbi.nlm.nih.gov/9118443
https://pubmed.ncbi.nlm.nih.gov/9118443
Autor:
Andrea Wang-Gillam, Robin L. Allgren, John Hilton, Albert C. Lockhart, Anthony J. Olszanski, Shinichi Yaguchi, Steven J. Cohen, Geoffrey I. Shapiro
Publikováno v:
Molecular Cancer Therapeutics. 12:B271-B271
Background: The PI3K signaling pathway regulates proliferation, differentiation, and cell death in human cancers. ZSTK474 is a novel and selective pan-Class I PI3K inhibitor that has demonstrated antitumor activity against a broad range of tumors in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cce8c57f8f2eaf0f7d553dfe5a0e7495
https://doi.org/10.1158/1535-7163.targ-13-b271
https://doi.org/10.1158/1535-7163.targ-13-b271